München, Germany - smartbax, a pioneering biotechnology research company, is delighted to announce the successful completion of its seed funding round, raising $1.29 million. The investment was led by High-Tech Gründerfonds, a prominent venture capital firm specializing in high-tech startups. The funds will be utilized to accelerate the development of smartbax's novel multi-targeted, antibacterial compounds, specifically designed to combat multi-drug resistant bacteria and difficult-to-treat biofilms.

The seed funding round attracted significant interest from investors, with High-Tech Gründerfonds spearheading the investment. Their expertise in supporting innovative startups aligns perfectly with smartbax's mission to revolutionize antibacterial research and develop practical solutions against drug-resistant pathogens.

Robert Macsics, Co-Founder of smartbax, expressed his gratitude for the support received, stating, "We are thrilled to have High-Tech Gründerfonds as our primary investor. This funding allows us to further advance our groundbreaking research and develop new therapeutics to combat the rising threat of multi-drug-resistant bacteria. We firmly believe that our innovative approach will have a substantial impact on public health, saving lives and improving patient outcomes."